seladelpar lysine
Brand and Other Names:
LIVDELZI
Mechanism of Action:
Seladelpar is a peroxisome proliferator-activated receptor (PPAR)-delta (δ) agonist. However, the mechanism by which seladelpar exerts its therapeutic effects in patients with PBC is not well understood.
Indications:
LIVDELZI is used to treat primary biliary cholangitis (PBC).
Route:
oral
Dose:
10 mg orally, once daily, with or without food.
Adverse Reactions:
Headache, abdominal pain, nausea, abdominal distension, dizziness.
Contraindication:
None
Warnings and Precautions:
Fractures: 4% incidence in clinical trial; monitor bone health.
Liver Test Abnormalities: Monitor ALT, AST, ALP, bilirubin. Discontinue if worsening occurs.
Biliary Obstruction: Avoid use in complete obstruction.
See package insert for full prescribing information.